MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
The impact of AMR
The consequences of AMR (Antimicrobial Resistance) on health, healthcare system and its economic burden are extraordinary. It has been estimated that multidrug resistant infections cause approximately 700,000 deaths worldwide each year. This number is likely to be underestimated due to poor reporting and surveillance. By 2050 it is projected that, unless action is taken, the burden of deaths from AMR could reach 10 million lives each year globally with $100 trillion GDP loss up to 2050.
By treating and preventing infections, antimicrobial medicines have enabled unique medical advances that appear as routine today - including chemotherapy, complex surgeries, and organ transplants, and the care of preterm infants and immunocompromised patients.
AMR is progressively undermining the viability of several types of medical interventions leaving patients highly vulnerable to resistant infections.
In the US, today more than two million infections per year are caused by bacteria that are resistant to at least first-line antibiotic treatments, costing the US health system 20 billion $ in excess costs each year.
In the EU, each year antibiotic resistance is responsible for about 33,000 deaths with an economic burden of about €1.1 billion for the health care systems.
(ref. WHO website)
